Patent application number | Description | Published |
20080227743 | Compositions and Kits for Treating Influenza - Compositions, kits and methods are provided for the treatment or prophylaxis of influenza. | 09-18-2008 |
20080241934 | Methods for reducing complexity of a sample using small epitope antibodies - The present invention relates generally to methods for reducing the complexity of a sample. More specifically, the present invention relates to proteomics, the measurement of the protein levels in biological samples, and analysis of proteins in a sample using antibodies that recognize small epitopes. | 10-02-2008 |
20080279819 | Combinations Therapy for Treatment of Demyelinating Conditions - The present invention provides novel methods and compositions for the treatment and prevention of demyelinating conditions. One demyelinating condition treated by the methods and compositions of the invention is multiple sclerosis. Also treated are symptoms associated with multiple sclerosis. | 11-13-2008 |
20090247481 | Compositions and Kits for Treating Influenza - Compositions, kits and methods are provided for the treatment or prophylaxis of influenza. | 10-01-2009 |
20090253728 | Methods and Compositions for Treating Nociceptive Pain - The present invention provides methods and compositions useful for the treatment and prevention of pain. | 10-08-2009 |
20090306051 | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders - The present invention relates to methods and compositions for treating CNS-related disorders. | 12-10-2009 |
20090326978 | Emergency Preparations for an Epidemic - Stockpiles and methods of stockpiling a combination antiviral therapy for responding to an epidemic viral outbreak are described. Methods and systems of inventory control for co-deployment of drugs used in combination during a pandemic are described. | 12-31-2009 |
20100022659 | Methods and Compositions for the Treatment of CNS-Related Conditions - The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease. | 01-28-2010 |
20100029665 | Methods and Compositions for Treating Migraine Pain - The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine. | 02-04-2010 |
20100047342 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-25-2010 |
20100137284 | Compositions for the Treatment and Prevention of Heart Disease and Methods of Using Same - The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease. This treatment is particularly effective in patients who have particularly heavy oxidative burdens, e.g. diabetics, patients with lung disorders, patients with sickle cell anemia and patients of Asian descent. | 06-03-2010 |
20100260838 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 10-14-2010 |
20100266684 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 10-21-2010 |
20100292216 | Methods and Compositions for the Treatment of Psychiatric Conditions - This invention relates to methods and compositions for treating psychiatric conditions, such as depression. | 11-18-2010 |
20110059169 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 03-10-2011 |
20110064804 | Methods and Compositions for the Treatment of CNS-Related Conditions - The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease. | 03-17-2011 |
20110189273 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 08-04-2011 |
20110230432 | COMPOSITIONS AND KITS FOR TREATING INFLUENZA - Compositions, kits and methods are provided for the treatment or prophylaxis of influenza. | 09-22-2011 |
20120045508 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-23-2012 |
20120046365 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-23-2012 |
20120058182 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 03-08-2012 |
20120264782 | COMPOSITIONS FOR THE TREATMENT OF CNS-RELATED CONDITIONS - The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
20120264783 | METHODS FOR THE TREATMENT OF CNS-RELATED CONDITIONS - The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
20120264829 | METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
20120264978 | COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides compostions for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
20120288560 | Methods for the Treatment of CNS-Related Conditions - The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. | 11-15-2012 |
20130131110 | Compositions for the Treatment of CNS-Related Conditions - The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 05-23-2013 |
20130165517 | Composition and Method for Treating Neurological Disease - A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine. | 06-27-2013 |
20130165527 | Method for Administering an NMDA Receptor Antagonist to a Subject - Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided. | 06-27-2013 |
20130317115 | Composition and Method for Treating Neurological Disease - A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day. | 11-28-2013 |
20140134243 | Compositions for the Treatment of CNS-Related Conditions - The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. | 05-15-2014 |
20140135529 | METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine xconcentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided. | 05-15-2014 |
20140179797 | Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject. | 06-26-2014 |
20140242163 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 08-28-2014 |
20140323582 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day. | 10-30-2014 |
20140336266 | METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided. | 11-13-2014 |
20140343152 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343153 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343154 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343163 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343164 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140356425 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 12-04-2014 |
20150045438 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150045439 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150045446 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150045447 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150045448 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150051292 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-19-2015 |
20150057355 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-26-2015 |
20150087721 | METHODS OF ADMINISTERING AMANTADINE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 03-26-2015 |